By shRNA-mediated knockdown we found that downregulation of TRIB2 strongly inhibits the viability and growth of enzalutamide-resistant cells, whereas benign prostatic hyperplasia (BPH-1) cells remained unaffected (Figs. 2, A–C and S4), suggesting that TRIB2 plays a critical but selective role in enzalutamide-resistant prostate cancer cells. Here, TRIB2 is linked to prostate carcinoma.